Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema
ConclusionTopical bromfenac 0.09% twice a day could enhance and sustain the efficacy of intravitreal ranibizumab in the treatment of diabetic macular edema without increasing the incidence of corneal side effects.
Source: International Ophthalmology - Category: Opthalmology Source Type: research
More News: Diabetes | Endocrinology | Eyes | Lucentis | Men | Opthalmology | Ranibizumab Injection | Study